May 2019 Vol 10, No 5
The field of oncology navigation is an integral part of a comprehensive oncology program to ensure the identification and effective removal of barriers to care, timely patient/family caregiver education, promotion of shared decision-making, patient advocacy, needed financial resources, and psychosocial support.
Find out if your navigation program is limited by these barriers.
Updated NCCN Breast Cancer Treatment Guideline Reflects Expanding Treatment Options for HR-Positive, HER2-Negative Disease
Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding.
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
The adjuvant use of the antibody-drug conjugate trastuzumab emtansine (T-DM1) led to a clinically meaningful and statistically significant improvement in invasive disease-free survival versus trastuzumab in patients with HER2-positive early breast cancer and residual invasive disease, despite the use of neoadjuvant chemotherapy plus HER2-targeted therapy, according to the preliminary results from the phase 3 KATHERINE trial reported at the 2018 San Antonio Breast Cancer Symposium.
The large, randomized TAM-01 clinical trial demonstrated that 5-mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo.
Atezolizumab plus nab-paclitaxel was the first immunotherapy combination to improve disease-free survival (DFS) and overall survival (OS) in women with metastatic triple-negative breast cancer (TNBC) versus placebo plus nab-paclitaxel in the overall analysis of the IMpassion130 trial. Survival improvement was even more robust in the PD-L1–positive cohort.
Adjuvant Chemotherapy May Not Be Needed for Localized Breast Cancer If pCR Is Attained on Neoadjuvant Chemotherapy
Reaching pathologic complete response (pCR) after neoadjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium.
The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.
Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of pancreatic cancer.
More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).
Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib, a BRAF inhibitor; binimetinib, a MEK inhibitor; and cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation.
Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Patients with Urothelial Cancer
Sacituzumab govitecan, a novel antibody-drug conjugate directed against Trop-2, induced response in nearly 33% of patients with heavily pretreated, relapsed, or refractory metastatic urothelial cancer.
Darolutamide, a Novel Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Darolutamide, an investigational androgen receptor inhibitor, significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) compared with placebo in a large phase 3 clinical trial.
Results 1 - 14 of 14